- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 29 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 25 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
NAG.30: 1 residues within 4Å:- Chain C: N.657
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain C: N.616, T.618, E.619
Ligand excluded by PLIPNAG.32: 1 residues within 4Å:- Chain C: N.603
Ligand excluded by PLIPNAG.33: 2 residues within 4Å:- Chain C: N.164, N.165
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain C: Y.28, N.61
Ligand excluded by PLIPNAG.35: 4 residues within 4Å:- Chain C: A.706, E.1072, N.1074
- Ligands: NAG.36
Ligand excluded by PLIPNAG.36: 2 residues within 4Å:- Chain C: N.1074
- Ligands: NAG.35
Ligand excluded by PLIPNAG.37: 1 residues within 4Å:- Chain C: N.234
Ligand excluded by PLIPNAG.38: 1 residues within 4Å:- Chain D: N.657
Ligand excluded by PLIPNAG.39: 1 residues within 4Å:- Chain D: N.616
Ligand excluded by PLIPNAG.40: 1 residues within 4Å:- Chain D: N.603
Ligand excluded by PLIPNAG.41: 1 residues within 4Å:- Chain D: N.165
Ligand excluded by PLIPNAG.42: 2 residues within 4Å:- Chain D: Y.28, N.61
Ligand excluded by PLIPNAG.43: 3 residues within 4Å:- Chain D: N.122, T.124, N.125
Ligand excluded by PLIPNAG.44: 5 residues within 4Å:- Chain D: A.706, E.1072, K.1073, N.1074
- Ligands: NAG.45
Ligand excluded by PLIPNAG.45: 4 residues within 4Å:- Chain D: N.1074, F.1075, T.1076
- Ligands: NAG.44
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain D: T.108, N.234, T.236
Ligand excluded by PLIPNAG.47: 1 residues within 4Å:- Chain G: N.657
Ligand excluded by PLIPNAG.48: 2 residues within 4Å:- Chain G: N.616, T.618
Ligand excluded by PLIPNAG.49: 1 residues within 4Å:- Chain G: N.603
Ligand excluded by PLIPNAG.50: 3 residues within 4Å:- Chain G: A.163, N.164, N.165
Ligand excluded by PLIPNAG.51: 4 residues within 4Å:- Chain G: N.331, T.333, Q.580, T.581
Ligand excluded by PLIPNAG.52: 6 residues within 4Å:- Chain D: Q.895
- Chain G: A.706, A.713, E.1072, N.1074
- Ligands: NAG.53
Ligand excluded by PLIPNAG.53: 2 residues within 4Å:- Chain G: N.1074
- Ligands: NAG.52
Ligand excluded by PLIPNAG.54: 3 residues within 4Å:- Chain G: G.232, I.233, N.234
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Peng, L. et al., Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. Nat Commun (2022)
- Release Date
- 2022-03-16
- Peptides
- Fab of antibody clone 2, light chain: AEH
Fab of antibody clone 2, heavy chain: BFI
Spike glycoprotein: CDG - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
LE
GH
EB
HF
FI
DC
CD
BG
A
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 29 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 25 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Peng, L. et al., Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. Nat Commun (2022)
- Release Date
- 2022-03-16
- Peptides
- Fab of antibody clone 2, light chain: AEH
Fab of antibody clone 2, heavy chain: BFI
Spike glycoprotein: CDG - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
LE
GH
EB
HF
FI
DC
CD
BG
A